KHRN.V - Khiron Life Sciences Corp.

TSXV - TSXV Delayed Price. Currency in CAD
1.67
-0.13 (-7.22%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close1.80
Open1.81
Bid1.67 x 0
Ask1.70 x 0
Day's Range1.64 - 1.83
52 Week Range0.87 - 1.99
Volume1,015,875
Avg. Volume608,880
Market Cap99.256M
Beta (3Y Monthly)-0.92
PE Ratio (TTM)N/A
EPS (TTM)-0.34
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.40
  • CNW Group14 days ago

    Khiron Life Sciences Corp. Announces Colombian Retail Distribution Partners for Kuida® CBD Cosmeceutical Brand

    TORONTO , Oct. 2, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), an integrated medical cannabis company with its core operations in Colombia , announced today that it has signed multi-channel distribution agreements for Kuida®, its first CBD-based skincare brand. As part of a robust strategy, Kuida® launches with secured distributor agreements that leverage their market reach, geographic location, scale and ability to ensure the Kuida® brand achieves its market potential.

  • CNW Group18 days ago

    Khiron Life Sciences Corp. Announces Formation of Wellness Business Unit and the Launch of Its First CBD Cosmeceutical Brand

    TORONTO , Sept. 28, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V) (KHRNF) (Frankfurt:A2JMZC), an integrated medical cannabis company with its core operations in Colombia , announced today the creation of Khiron Wellness, and the launch of Kuida®, its first CBD-based skincare brand. With this achievement, Kuida® becomes the first mass-market CBD-based brand approved by INVIMA, Colombia´s health agency, and available for sale in Colombia . Khiron's Wellness business unit is focused on cosmeceutical and nutraceutical products, offering the full benefits of cannabis to consumers across Latin America .

  • CNW Group19 days ago

    Khiron Life Sciences Signs Non-Binding MOU to Enter Chilean Medical Cannabis Market with Country's Only Licensed Producer, Fundacion Daya and DayaCann

    TORONTO , Sept. 27, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V) (KHRNF) (Frankfurt:A2JMZC), an integrated medical cannabis company with its core operations in Colombia , announced today that the Company has signed a non-binding memorandum of understanding with Fundacion Daya, Chile's leading medical cannabis institution and the holder of Chile's only medical cannabis license through DayaCann, a joint venture entity established between Fundacion Daya and AusCann Group Holdings Ltd.

  • CNW Group20 days ago

    Khiron Life Sciences Announces Incorporation into Horizons Emerging Marijuana Growers Index ETF

    Khiron Life Sciences Announces Incorporation into Horizons Emerging Marijuana Growers Index ETF

  • CNW Group20 days ago

    Khiron Life Sciences Director and Former President of Mexico, Mr. Vicente Fox to Present Keynote Address at Global Cannabis Business Conference in Jamaica

    Khiron Life Sciences Director and Former President of Mexico, Mr. Vicente Fox to Present Keynote Address at Global Cannabis Business Conference in Jamaica

  • PR Newswirelast month

    Khiron Life Sciences Corp. to Present at Virtual Investor Conference

    Live Webcast Scheduled for September 12, 2018 , 2:00pm EDT , followed by Q&A TORONTO , Sept. 12, 2018 /PRNewswire/ --  KHIRON LIFE SCIENCES CORP. ("Khiron" or the "Company") (TSXV: ...

  • CNW Grouplast month

    Khiron announces closing of $12.93 million prospectus financing including full exercise of over-allotment option

    TORONTO , Sept. 12, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN, OTCQB:KHRNF), a Canadian integrated medical cannabis company with its core operations in Colombia , is pleased to announce that it has closed today its previously announced best efforts short form prospectus offering of common shares ("Common Shares"), including the exercise in full of the over-allotment option (the "Offering"). A total of 14,375,000 Common Shares were sold at a price of $0.90 per Common Share (the "Issue Price") for aggregate gross proceeds of $12,937,500 (including the exercise in full of the over-allotment option).

  • PR Newswirelast month

    Live Investor Conference & Webinar: Cannabis Industry Companies Present September 12

    Cannabis company executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , Sept. 6, 2018 /PRNewswire/ -- VirtualinvestorConferences.com and KCSA Strategic Communications ...

  • CNW Group2 months ago

    IIROC Trading Resumption - KHRN

    IIROC Trading Resumption - KHRN

  • CNW Group2 months ago

    Khiron Announces Pricing of Marketed Short Form Prospectus Offering of Common Shares

    TORONTO , Aug. 23, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN , OTCQB:KHRNF), a Canadian integrated medical cannabis company with its core operations in Colombia , is pleased to report that it has priced and sized its previously announced marketed offering of common shares at a price of $0.90 per share to raise aggregate gross proceeds of up to $11,250,000 (the "Offering"). The Offering will be conducted through a syndicate of agents on a best efforts basis led by Canaccord Genuity Corp., and including GMP Securities L.P., Sprott Private Wealth LP, and Cormark Securities Inc. (together, the "Agents").  The Company has also granted the Agents with an over-allotment option to offer and sell up to an additional 15% of the number of common shares sold in the Offering.

  • GlobeNewswire2 months ago

    Khiron Announces Filing of Marketed Short Form Prospectus Offering of Common Shares

    Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN, OTCQB:KHRNF), a Canadian integrated medical cannabis company with its core operations in Colombia, reports that it has filed a preliminary short form prospectus with the securities regulatory authorities in each of the provinces of Canada, other than Québec, in connection with a marketed offering of common shares of the Company (the “Offering”). The size of the Offering and price will be determined in the context of the market. The Offering will be conducted through a syndicate of agents on a best efforts basis led by Canaccord Genuity Corp., and including GMP Securities L.P., Sprott Private Wealth LP, and Cormark Securities Inc. (together, the “Agents”).  The Company has also granted the Agents with an over-allotment option to offer and sell up to an additional 15% of the number of common shares sold in the Offering.

  • CNW Group2 months ago

    IIROC Trading Halt - KHRN

    IIROC Trading Halt - KHRN

  • CNW Group2 months ago

    Khiron lists on OTCQB Venture Market

    TORONTO , Aug. 15, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V) (KHRNF), a Canadian integrated medical cannabis company with its core operations in Colombia , announced today that the Company has successfully applied and been accepted for listing to the OTCQB Venture Market stock platform. The common shares of the Company will trade under the ticker symbol KHRNF. The OTCQB Venture Market is for early-stage and developing U.S. and international companies.

  • CNW Group2 months ago

    Khiron CEO Alvaro Torres to Speak at Global Cannabis Business Conference in Toronto

    TORONTO , Aug. 13, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), a Canadian integrated medical cannabis company with its core operations in Colombia, announced today that Company co-founder and CEO Mr. Alvaro Torres will participate in an international panel session at the MJBizCon INT'L marijuana business conference, taking place at the Metro Toronto Convention Centre, Aug. 14th – 16th. Mr. Torres will participate in the How to Use Science and Research to Boost Your Business panel session on Thurs., Aug. 16th at 2:00 p.m.

  • Benzinga2 months ago

    Aurora Acquires HotHouse Consulting, GrowForce Gets $29M Investment, Khiron Buys Colombian Health Network

    The funds will serve as general working capital and support cultivation expansion and asset acquisition. “With this capital raise, additional access to growth capital and key strategic partnerships in place, GrowForce is well-positioned to consolidate a fragmented cannabis industry in Canada and international markets,” James Lowe, executive vice president of operations for GrowForce, said in a statement. Aurora Cannabis Inc (TSE: ACB)(OTC: ACBFF) announced it signed a letter of intent to acquire the cannabis business of HotHouse Consulting Inc., which supports about 50 customers globally.

  • CNW Group2 months ago

    IIROC Trading Resumption - KHRN

    IIROC Trading Resumption - KHRN

  • CNW Group2 months ago

    Khiron Signs Letter of Intent to Acquire Colombia's Leading Health Network

    TORONTO , Aug. 7, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), a Canadian integrated medical cannabis company with its core operations in Colombia , announced today that it has entered into a non-binding letter of intent ("LOI") with the Latin American Institute of Neurology and the Nervous System ("ILANS"), one of the most respected, fastest growing, and largest health service provider networks in Colombia and Latin America . Through the proposed acquisition of the Bogata clinic platform, the ILANS network represents an estimated 100,000 patients, and once closed, will position Khiron with approximately $10.5 million of revenue and $1.8 million of EBITDA (audited for the year ended December 31, 2017 ). The LOI sets forth the terms whereby Khiron will acquire all the issued and outstanding shares of ILANS through Khiron's wholly-owned subsidiary, Khiron Colombia SAS.

  • CNW Group2 months ago

    IIROC Trading Halt - KHRN

    IIROC Trading Halt - KHRN

  • CNW Group2 months ago

    Khiron Expands Medical Cannabis Cultivation Capacity and Advances Towards Commercialization

    TORONTO , Aug. 2, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), a Canadian integrated medical cannabis company with its core operations in Colombia , announced today it has notified the Colombian Ministry of Justice that the Company has expanded its cultivation area to 17.5 hectares of prime agricultural land near Ibague, Colombia . The cultivation site has an ideal climate profile, abundance of water, power, and skilled labour to scale cultivation and production.

  • CNW Group3 months ago

    IIROC Trading Resumption - KHRN

    IIROC Trading Resumption - KHRN

  • CNW Group3 months ago

    Khiron Appoints Former Mexican President Vicente Fox to Board of Directors

    TORONTO , July 17, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), a Canadian integrated medical cannabis company with its core operations in Colombia , announced today that the Company has appointed former President of Mexico Mr. Vicente Fox Quesada to its board of directors, effective immediately. Mr. Fox will be a strategic advisor and brand ambassador for the Company, furthering the Company's education and brand leadership interests across Latin America .

  • CNW Group3 months ago

    IIROC Trading Halt - KHRN

    IIROC Trading Halt - KHRN

  • CNW Group4 months ago

    Khiron Expands Leadership Team with Appointment of Chris Naprawa as President

    TORONTO , June 26, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), a Canadian integrated medical cannabis company with its core operations in Colombia , announced today the appointment of Chris Naprawa as President, effective immediately. Mr. Naprawa, who will report to Alvaro Torres , CEO, will lead Khiron's capital markets activities, including outreach to existing and potential shareholders in Canada and internationally.

  • CNW Group4 months ago

    Khiron Appoints Internationally Recognized Medical Cannabis Specialist Dr. Maria Fernanda Arboleda as Medical Director

    TORONTO , June 25, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), a Canadian integrated medical cannabis company with its core operations in Colombia , announced today that it has appointed Dr. Maria Fernanda Arboleda as Medical Director.